Insights
Search Results
Client Highlights
6.11.26
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
4.08.26
Wilson Sonsini Advises Sidewinder Therapeutics on Oversubscribed $137 Million Series B Financing
On April 8, 2026, Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific antibody-drug conjugates (ADCs) for the treatment of cancer, announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed, as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Sidewinder Therapeutics on the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
News Articles
7.08.25
Miranda Biven and Karen Deschaine Honored Among SDBJ’s Women of Influence in Law
On July 7, 2025, Wilson Sonsini partners Miranda Biven and Karen Deschaine were recognized in the San Diego Business Journal’s 2025 special edition of “Women of Influence in Law,” which honors women trailblazers in the legal field in the San Diego region.
News Articles
4.09.25
Miranda Biven Named Among SDBJ's 2025 "Leaders of Influence in Technology"
On April 1, 2025, Wilson Sonsini partner Miranda Biven was named among the 2025 "Leaders of Influence in Technology” in a special supplement by the San Diego Business Journal, recognizing individuals who are making a significant impact in the tech industry.
Client Highlights
4.07.25
Wilson Sonsini Advises RayThera on $110 Million Series A
On April 4, 2025, San Diego-based RayThera, Inc., a biotechnology company focused on small molecule therapies in immunology, announced the successful completion of a $110 million Series A round co-led by Foresite Capital and OrbiMed Advisors, with participation from TTM Capital. Wilson Sonsini Goodrich & Rosati advised RayThera on the transaction.
Client Highlights
3.17.25
Firm Advises Taiho Pharmaceutical on Acquisition of Araris Biotech for Up to $1.1 Billion
On March 17, 2025, Taiho Pharmaceutical Co., Ltd., an R&D-driven specialty pharmaceutical company focusing on the fields of oncology and immune-related diseases, and Araris Biotech AG, a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), announced that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will acquire Araris. Under the terms of the agreement, Taiho Pharmaceutical will pay $400 million at closing, with the potential for additional milestone payments of up to $740 million. The acquisition, which is expected to be completed in the first half of 2025, follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023. Wilson Sonsini Goodrich & Rosati advised Taiho Pharmaceutical on the acquisition.
Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and is pioneering the development of best-in-class ADCs with superior design, high linker solubility, and simple manufacturing that address the shortcomings of current generation ADCs. Taiho Pharmaceutical, in addition to antimetabolites, has established and created novel drugs through its proprietary small molecule drug discovery platform, Cysteinomix, enhancing cancer treatment and contributing to patient care. By acquiring Araris' innovative ADC drug discovery technology platform, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
The Wilson Sonsini team that advised Taiho Pharmaceutical on the transaction included Miranda Biven, Jason Breen, Nellie Brutocao, and Ken Clark.
For more information, please see the companies’ joint news release. Additional coverage is available on Fierce Biotech and BioSpace.
Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and is pioneering the development of best-in-class ADCs with superior design, high linker solubility, and simple manufacturing that address the shortcomings of current generation ADCs. Taiho Pharmaceutical, in addition to antimetabolites, has established and created novel drugs through its proprietary small molecule drug discovery platform, Cysteinomix, enhancing cancer treatment and contributing to patient care. By acquiring Araris' innovative ADC drug discovery technology platform, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
The Wilson Sonsini team that advised Taiho Pharmaceutical on the transaction included Miranda Biven, Jason Breen, Nellie Brutocao, and Ken Clark.
For more information, please see the companies’ joint news release. Additional coverage is available on Fierce Biotech and BioSpace.
Client Highlights
1.13.25
Wilson Sonsini Advises Light Horse Therapeutics on $62 Million Series A
Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its debut $62 million Series A financing. The financing, announced on January 9, 2025, was led by founding investor Versant Ventures and included Mubadala Capital as well as three strategic investors: Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie. Light Horse is the latest company started by Versant’s Inception Discovery Engine, and its scientific co-founders are Brian Liau, Ph.D., Ben Cravatt, Ph.D., and Nathanael Gray, Ph.D.
Client Highlights
1.13.25
Wilson Sonsini Advises Light Horse Therapeutics on Strategic Collaboration with Novartis
Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its multi-target collaboration with Novartis to identify and develop therapeutics using the biotech’s proprietary platform. Under the terms of the agreement, announced on January 9, 2025, Light Horse will receive a $25 million upfront payment. The company is also eligible for $1 billion in further research, development, and sales milestones, in addition to royalties on licensed therapeutics. Further details are undisclosed.
Client Highlights
12.20.24
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio
On December 19, 2024, Aadi Bioscience announced that it had entered into an agreement to sell its commercial drug product FYARRO® to KAKEN Pharmaceutical for $100 million, an agreement to sell and issue $100 million of equity in a PIPE financing, and an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, and Hangzhou DAC, a global leader in ADC innovation.
Client Highlights
10.22.24
Wilson Sonsini Advises Novo Holdings and F-Prime Capital on AvenCell’s $112 Million Series B
On October 22, 2024, AvenCell Therapeutics, a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, announced that it has raised $112 million in Series B financing. The financing was led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences. Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction.